Bendamustine HCl Injection, 100mg/4mL (25mg/mL), One 4 mL Multiple-Dose Vial, Rx only, Manufactured for Baxter Health... — FDA record D-1103-2023

Reported completed

Status as reported in the agency record. FDA warns that enforcement status may not track the current recall lifecycle; check the current official notice.

Source date Aug 14, 2023. Retrieved Oct 1, 2026. Last updated Oct 1, 2026.

Archive changed Oct 1, 2026. USDA FSIS records are unavailable; check FSIS directly. Source coverage and dates.

What the record says

Product
Bendamustine HCl Injection, 100mg/4mL (25mg/mL), One 4 mL Multiple-Dose Vial, Rx only, Manufactured for Baxter Healthcare Corporation, Deerfield, IL 60015, NDC 10019-079-01.
Reason
Labeling: Missing Label; customer complaint received that labels were partially or completely peeled off injection vial.
Classification
Class III
Recalling firm
Baxter Healthcare Corporation
Quantity
13,502 vials
Agency-reported status
Completed
Source record identifier
D-1103-2023

Open the official record

What the recall classes mean. Classification is an agency assessment, not individual medical advice.

Lot and product identifiers

Label fieldDetails supplied by the agency
Lot, code or applicabilityLots: 3A004A, 3A004B, Exp 12/31/2024; 3B005A, Exp 1/31/2025

Match all identifying details in the current notice. A brand name alone is not enough.

Distribution

Nationwide in the U.S.A.

States below are derived from the distribution text, including nationwide wording. They are not inferred from the firm's address.

Dates in the source

Report date
Aug 30, 2023
Recall initiation date
Aug 14, 2023
Center classification date
Aug 24, 2023

FDA company pages use the listing date; enforcement records use initiation dates; CPSC uses recall date; NHTSA uses report-received date. These dates are not interchangeable.

Related records